Additionally, two small studies in participants presenting with antiretroviral-induced neuropathy found significant reduction in subjects' mean pain intensity with oral ALCAR (1-3 g/day) for 4 to 24 weeks, but no effect on objective neurophysiological parameters was found (82, 83)
These probes offer tunable excitation and emission wavelengths, enabling multiplexed imaging alongside other fluorescent markers
In 2023 the FDA placed BPC-157 in Category 2 of its 503A bulk-substances review the group flagged as presenting significant safety risks for compounding reflecting concerns about immunogenicity, impurities, and lack of human data
That added component is what shifts the blend more clearly toward inflammation-related and barrier-oriented research logic, rather than a repair-only emphasis
This includes issues like heart disease, nerve damage, and kidney problems